Prognostic role of neutrophil-to-lymphocyte ratio in diffuse large B cell lymphoma patients: an updated dose–response meta-analysis
Open Access
- 22 August 2018
- journal article
- research article
- Published by Springer Nature in Cancer Cell International
- Vol. 18 (1) , 119
Abstract
The neutrophil-to-lymphocyte ratio (NLR), a biomarker for systematic inflammation, has been recently identified as a prognostic factor for various types of both solid and hematologic malignancies. Here we conducted an updated dose–response meta-analysis to investigate whether NLR can be served as a prognostic biomarker in diffuse large B cell lymphoma (DLBCL). We systematically searched PubMed, Embase, ISI Web of Science and CNKI for relevant studies. Odds ratios or hazards ratios (HRs) with corresponding 95% confidence intervals (CIs) were pooled to estimate the association between NLR and clinicopathological parameters or survival of cancer patients. Eleven trials with 2515 DLBCL patients were included in the meta-analysis. The results revealed that elevated pretreatment NLR was significantly associated with elder age, advanced Ann Arbor stage, higher incidence rate of B symptoms and bone marrow involvement, and higher lactate dehydrogenase level, etc. Moreover, increased NLR also predicted poorer overall survival (HR 1.826, 95% CI 1.238–2.692) and progression-free survival/event-free survival (PFS/EFS) (HR 1.591, 95% CI 1.124–2.252). And two-stage dose–response meta-analysis revealed non-linear association between increased NLR and risk of mortality in DLBCL patients. DLBCL patients with higher NLR are more likely to have poorer prognosis than those with lower NLR.Keywords
Funding Information
- The natural science funds of china (81500172, 81670197, 81202962)
- the Integrated Innovative Team for Major Human Diseases Program of Tongji Medical College, HUST
- the Clinical Research Physician Program of Tongji Medical College, HUST
This publication has 41 references indexed in Scilit:
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and ElaborationPLOS Medicine, 2012
- New Strategies in Diffuse Large B-cell Lymphoma: Translating Findings from Gene Expression Analyses into Clinical PracticeClinical Cancer Research, 2011
- The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applicationsBlood, 2011
- Improving Outcomes for Patients With Diffuse Large B-Cell LymphomaCA: A Cancer Journal for Clinicians, 2010
- Predicting survival for diffuse large B‐cell lymphoma patients using baseline neutrophil/lymphocyte ratioAmerican Journal of Hematology, 2010
- Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphomaLeukemia, 2010
- Dose‐response analyses using restricted cubic spline functions in public health researchStatistics in Medicine, 2010
- Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now?Leukemia & Lymphoma, 2009
- Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and LymphomasCancer Research, 2009
- Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarrayBlood, 2004